Hafnium Oxide Containing Nanoparticles NBTXR3

Drug Overview

The Hafnium Oxide Containing Nanoparticles NBTXR3 (also known as NBTXR3 or Hensify) is a first-in-class, investigational radio-enhancer designed to amplify the effects of radiotherapy. It is composed of functionalized hafnium oxide (HfO₂) nanoparticles.

NBTXR3 is not a drug in the traditional pharmacological sense, but a physical agent. These nanoparticles are injected directly into a solid tumor. Once inside, they remain inert until they are activated by standard ionizing radiation. Because hafnium has a high atomic number (Z = 72), it is far more efficient at absorbing X-rays than human tissue. This allow for a “magnification” of the radiation dose within the tumor itself while sparing the surrounding healthy organs.

• Generic Name: NBTXR3.
• Brand Name: Hensify (CE marked in Europe for certain indications).
• Drug Class: Radio-enhancer / Nanomedicine / Medical Device (in some jurisdictions).
• Composition: Hafnium oxide (HfO₂) nanoparticles.
• Route of Administration: Intratumoral (IT) injection.
• FDA Approval Status: Investigational. As of March 2026, NBTXR3 is not yet FDA-approved. It has received Fast Track Designation for the treatment of locally advanced head and neck cancers and is currently being evaluated in a global Phase III trial (NANORAY-312).

What Is It and How Does It Work? (Mechanism of Action)

NBTXR3 functions through a purely physical mechanism called “Dose Enhancement.”

The Physics of Hafnium

Standard radiotherapy relies on X-rays interacting with the water in human cells to create free radicals that damage DNA. However, soft tissue is not very “dense” to radiation. Hafnium is a “heavy” metal that is much more likely to interact with incoming photons.

Molecular Level Mechanisms

1. Direct Injection & Persistence: The nanoparticles are injected into the tumor one time. Because of their size and coating, they are “eaten” by the cancer cells (endocytosis) and remain inside the tumor for the entire duration of a multi-week radiotherapy course.
2. Photon Absorption: When the radiotherapy beam passes through the tumor, the hafnium atoms absorb the X-ray energy significantly more than the surrounding cells.
3. Secondary Electron Emission: The hafnium atoms then release a high concentration of secondary electrons (photoelectrons and Auger electrons).
4. Massive Free Radical Generation: These secondary electrons travel short distances within the tumor cell, creating a massive “shower” of reactive oxygen species (ROS).
5. Direct DNA Damage: The high density of ROS causes complex double-strand DNA breaks that the cancer cell cannot repair, leading to cell death (necrosis or apoptosis).
6. Abscopal Effect (Immune Priming): Recent research suggests that the violent destruction of the tumor by NBTXR3 releases “danger signals” and tumor antigens, which can help the patient’s immune system recognize and attack cancer elsewhere in the body.

FDA-Approved Clinical Indications

There are currently no FDA-approved indications for NBTXR3.

In Europe, it has received a CE mark for the treatment of Soft Tissue Sarcoma. In the U.S. and globally, it is being investigated for:

• Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC): Primarily for elderly or frail patients who cannot tolerate aggressive chemotherapy.
• Soft Tissue Sarcoma: To shrink tumors before surgery (neoadjuvant).
• Liver Cancers (HCC) and Pancreatic Cancer: Investigated for use with SBRT (Stereotactic Body Radiation Therapy).
• Immunotherapy Combinations: Studied alongside PD-1 inhibitors (like Pembrolizumab) to see if NBTXR3 can turn “cold” tumors “hot.”

Dosage and Administration Protocols

NBTXR3 is unique because it is usually a one-time administration for an entire course of treatment.

Clinical Efficacy and Research Results

As of 2024 through early 2026, clinical trials have shown that NBTXR3 significantly increases the “kill rate” of radiation.

• Soft Tissue Sarcoma (Act.In.Sarc Study): In a Phase II/III trial, patients receiving NBTXR3 plus radiotherapy had a Pathological Complete Response (pCR) rate double that of those receiving radiotherapy alone (16% vs 8%).
• Head and Neck Cancer: Early data from the Study 102 and NANORAY-312 trials show that the nanoparticles are well-tolerated in elderly patients and can achieve high rates of local tumor control without increasing the severity of radiation-induced skin or mouth sores.
• Immune Response: 2025 data confirmed that NBTXR3 increases the infiltration of CD8+ T-cells into the tumor, supporting its use as an “immuno-primer.”

Safety Profile and Side Effects

The side effects of NBTXR3 are generally localized to the injection site or are related to the radiotherapy itself.

Common Side Effects:

• Injection Site Pain: Temporary discomfort following the intratumoral injection.
• Pyrexia (Fever): A transient “flu-like” response shortly after the injection (reported in ~10% of patients).
• Radiotherapy Side Effects: Because the drug makes radiation more effective, local side effects (like redness or inflammation) may occur, though trials have not yet shown a significant increase in overall radiation toxicity.

Serious Risks:

• Tumor Lysis Syndrome: Rapid destruction of a very large tumor could theoretically stress the kidneys, though this is rare with radiotherapy.
• Migration: There is a theoretical risk of nanoparticles moving into the bloodstream, though hafnium oxide is biologically inert and usually remains “trapped” in the tumor.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, NBTXR3 is being used to study “Micro-environment Modulation.” Researchers are investigating how the localized destruction of tumor tissue by hafnium nanoparticles affects the surrounding Mesenchymal Stem Cells (MSCs). There is hope that by clearing the tumor more effectively, NBTXR3 can create a “cleaner” niche that allow healthy tissue-resident stem cells to regenerate the area once the cancer is gone.

Patient Management and Practical Recommendations

Pre-treatment Tests:

• High-Resolution Imaging (CT/MRI): To precisely calculate the volume of the tumor for dosing.
• Coagulation Profile: To ensure the patient can safely undergo an intratumoral injection without excessive bleeding.

Precautions:

• Radiotherapy Planning: The physics team must adjust the radiation plan to account for the “shadowing” or density of the hafnium particles during imaging.
• Single Use: NBTXR3 should not be re-administered to the same site unless specified by a protocol.

“Do’s and Don’ts” List:

• DO inform your radiotherapy team exactly where and when the NBTXR3 was injected.
• DO expect the tumor area to feel slightly “heavy” or dense immediately after the injection.
• DON’T ignore a high fever or severe chills that occur within 24 hours of the injection.
• DON’T undergo the injection if you have an active infection at the site of the tumor.

Legal Disclaimer

The information provided is for educational purposes only and does not constitute medical advice. NBTXR3 is an investigational agent and is not currently approved by the US FDA. It is available only through participation in approved clinical trials. Always consult with a qualified radiation oncologist or surgeon regarding your diagnosis and eligibility for research.